Recombinant FVII (Kogenate) treatment of previously untreated patients (PUPs) with hemophilia A: Update of safety, efficacy and inhibitor development after seven study years

被引：0

作者：

Lusher, J

Arkin, S

Abildgaard, CF

Hurst, A

机构：

[1] MT SINAI SCH MED, NEW YORK, NY USA

[2] WAYNE STATE UNIV, DETROIT, MI USA

[3] UNIV CALIF DAVIS, SACRAMENTO, CA 95817 USA

[4] BAYER CORP, BERKELEY, CA USA

来源：

THROMBOSIS AND HAEMOSTASIS | 1997年

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

下载

页码：PD664 / PD664

页数：1

共 50 条

[1] Kogenate treatment of previously untreated patients (PUPs) with hemophilia A: Update of safety, efficacy, and inhibitor development after seven study years.
Lusher, J
Arkin, S
Abildgaard, CF
Hurst, D
BLOOD, 1996, 88 (10) : 1755 - 1755
[2] RECOMBINANT FVIII (KOGENATE) TREATMENT OF PREVIOUSLY UNTREATED PATIENTS (PUPS) WITH HEMOPHILIA-A - UPDATE OF SAFETY, EFFICACY AND INHIBITOR DEVELOPMENT AFTER 5 STUDY YEARS
LUSHER, JM
ARKIN, S
ABILDGAARD, CF
HURST, D
PEDIATRIC RESEARCH, 1995, 37 (04) : A161 - A161
[3] KOGENATE TREATMENT OF PREVIOUSLY UNTREATED PATIENTS (PUPS) WITH HEMOPHILIA-A - UPDATE OF SAFETY, EFFICACY, AND INHIBITOR DEVELOPMENT AFTER 5 STUDY YEARS
LUSHER, J
ARKIN, S
ABILDGAARD, CF
HURST, D
BLOOD, 1994, 84 (10) : A239 - A239
[4] RECOMBINANT-FVIII (KOGENATE) TREATMENT OF PREVIOUSLY UNTREATED PATIENTS (PUPS) WITH HEMOPHILIA-A - UPDATE OF SAFETY, EFFICACY, AND INHIBITOR DEVELOPMENT AFTER 5 STUDY YEARS
LUSHER, J
ARKIN, S
ABILDGAARD, CF
HURST, D
THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 1012 - 1012
[5] Safety and efficacy of KOGENATE® Bayer in previously untreated patients (PUPS) and minimally treated patients (MTPs)
Giangrande, PLF
HAEMOPHILIA, 2002, 8 : 19 - 22
[6] INHIBITOR DEVELOPMENT IN PREVIOUSLY UNTREATED PATIENTS (PUPS) WITH HEMOPHILIA RECEIVING KOGENATE - 4.5 YEAR FOLLOW-UP DATA, INCLUDING RESPONSE TO IMMUNE TOLERANCE (IT) WITH KOGENATE
LUSHER, J
ARKIN, S
ABILDGAARD, C
INWOOD, M
HILGARTNER, M
HURST, D
PEDIATRIC RESEARCH, 1994, 35 (04) : A165 - A165
[7] Safety, efficacy and inhibitor development in previously untreated patients (PUPs) treated exclusively with recombinant B domain deleted recombinant FVIII (BDDrFVIII).
Lusher, JM
Gringeri, A
Hann, I
Rodriguez, D
BLOOD, 1999, 94 (10) : 234A - 235A
[8] Anti-FVIII inhibitor incidence in previously untreated patients (PUPs) with hemophilia exposed to Kogenate® (GIPSI-German-Italian PUP study on inhibitor)
Gringeri, A
Kreuz, W
Escuriola-Ettinghausen, C
Santagostino, E
Saguer, IM
Bader, R
Budde, U
Mannucci, PM
THROMBOSIS RESEARCH, 1998, 91 (03) : S8 - S9
[9] RECOMBINANT FACTOR-VIII FOR THE TREATMENT OF PREVIOUSLY UNTREATED PATIENTS WITH HEMOPHILIA-A - SAFETY, EFFICACY, AND DEVELOPMENT OF INHIBITORS
LUSHER, JM
ARKIN, S
ABILDGAARD, CF
SCHWARTZ, RS
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (07): : 453 - 459
[10] SAFETY, EFFICACY AND INHIBITOR RISK OF RECOMBINANT FACTOR-VIII (RECOMBINATE(R)) IN A COHORT OF PREVIOUSLY UNTREATED PATIENTS (PUPS) WITH SEVERE HEMOPHILIA-A
BRAY, GL
COURTER, S
LYNES, M
LEE, M
GOMPERTS, E
THROMBOSIS AND HAEMOSTASIS, 1993, 69 (06) : 1205 - 1205

← 1 2 3 4 5 →